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Background: miRNAs are involved in osteosarcoma (OS) chemoresistance, and TWIST reportedly enhances
cisplatin-induced OS cell apoptosis by inhibiting multiple signaling pathways. In this study, we profiled miRNAs
differentially expressed in chemoresistant OS, with a focus to identify miRNAs that regulate TWIST expression and
OS chemoresistance.
Methods: OS patients who showed <90% tumor necrosis after neochemotherapy were defined as poor responders
(chemoresistant), and those who showed ≥90% tumor necrosis were defined as good responders (control). miRNA
microarray analysis was carried out with a discovery cohort (n = 12) of age-, sex- and tumor stage-matched
chemoresistant and control OS patients.
Results: Among the up-regulated miRNAs in chemoresistant OS samples, miR-33a was verified to down-regulate
TWIST expression, which was supported by an inverse miRNA-33a/TWIST expression trend in the validation cohort
(n = 70), target-sequence-specific inhibition of TWIST-3′ untranslated region-luciferase reporter activity by miR-33a,
and alteration of TWIST expression by overexpression or inhibition of miR-33a in human OS cell lines. In Saos-2
cells treated with cisplatin, inhibition of miR-33a by antagomir-33a markedly increased cell apoptosis, which was
enhanced by overexpression of TWIST. The apoptosis-inducing effect of TWIST overexpression was reversed by
overexpression of miR-33a. In MG-63 cells, overexpression of miR-33a significantly decreased cisplatin-induced cell
apoptosis, which was enhanced by knockdown of TWIST. Antagomir-33a significantly increased cisplatin-induced
cell apoptosis, which was reversed by knockdown of TWIST.
Conclusions: We have demonstrated in this study that miR-33a is up-regulated in chemoresistant OS and that the
miR-33a level is negatively correlated with the TWIST protein level in OS. Our in vitro data indicate that miR-33a
promotes OS cell resistance to cisplatin by down-regulating TWIST; on the other hand, inhibition of miR-33a by
antagomir-33a enhances cisplatin-induced apoptosis in OS cells by up-regulating TWIST expression. The findings
suggest that inhibition of miR-33a/TWIST signaling could be a potential new strategy to enhance neoadjuvant
chemotherapy for OS.
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Osteosarcoma (OS) is the most frequent malignant bone
tumor in children and adolescents, comprising 2.4% of
all malignancies in pediatric patients [1]. The 5-year sur-
vival rate of OS patients has significantly improved over
the past decades to approximately 60-70% since the
introduction of combinatorial chemotherapy [2]. How-
ever, a significant proportion of OS patients still respond
poorly to chemotherapy, and they have a risk of local re-
lapse or distant metastasis even after curative resection
of the primary tumor and intensive chemotherapy.
Standard chemotherapy of OS is based on a combination
of different drugs: neoadjuvant therapy with methotrex-
ate, cisplatin, and doxorubicin followed by surgery and
post-operative chemotherapy (methotrexate, cisplatin,
doxorubicin, cyclophosphamide, and vincristine). Des-
pite this, approximately 30% of patients relapse or
develop metastasis [3]. The lack of responsiveness to
chemotherapy due to intrinsic or acquired chemoresis-
tance is the major reason for poor survival and disease
relapse of OS patients [4]. Recently, novel molecular tar-
geted drugs have emerged, but they have not been well
established for the treatment of OS [5]. In addition, the
molecular mechanisms underlying OS chemoresistance
remain largely obscure. Hence, identification of factors
that contribute to OS chemoresistance and elucidation
of the underlying mechanisms will be pivotal in the de-
velopment of new therapeutic strategies.
TWIST, also known as TWIST1, belongs to the basic
helix-loop-helix (bHLH) transcription factor family. Dur-
ing embryonic development, TWIST plays an essential
role in specification of the mesoderm and differentiation
of the mesoderm-derived tissues [6]. Twist haploinsuffi-
ciency was shown to upset bone tissue in both mice and
humans [7,8]. In homogeneous cohort of OS patients,
the TWIST gene was frequently deleted in the tumors at
diagnosis, and its haploinsufficiency was significantly
correlated with a poorer patient outcome [6,9]. It has
been reported that TWIST decreases OS cell survival
against cisplatin by inhibiting β-catenin signaling and
endothelin-1/endothelin A receptor signaling pathways
[10,11], suggesting that TWIST is an important negative
regulator in the development of OS chemoresistance.
MicroRNAs (miRNAs) are noncoding small RNAs,
usually 18–25 nucleotides in length, which repress
translation and cleave mRNA by base-pairing to the
3′-untranslated region (UTR) of the target genes [12].
Knowledge of individual miRNAs effecting develop-
mental biology, cellular differentiation programs, and
oncogenesis continues to grow [13]. Differences in the
miRNA expression profiles detected between cancer
cells and their normal counterparts have revealed that
miRNAs are involved in the pathogenesis of cancer [14].
In addition, miRNAs may play multiple roles as tumorsuppressors, oncogenes, or both in some cases [15]. The
biological properties of miRNAs may make them useful
as diagnostic and prognostic tools as well as therapeutic
targets in various cancers, including OS. A number of
miRNAs reportedly are involved in OS tumorigenesis
and chemoresistance [13].
In the present study, we screened for miRNAs regulat-
ing TWIST expression in human OS and explored




From November 2010 to May 2013, we enrolled two co-
horts of OS patients. The discovery cohort consists of
six Han Chinese OS patients who showed <90% tumor
necrosis (mean 70.8% ± 9.2%) after chemotherapy and
were defined as poor responders at the third Xiangya
Hospital of Central South University [16]. Another six
age-, sex-, and tumor stage-matched Han Chinese OS
patients, who showed ≥90% tumor necrosis (mean
94.1% ± 2.8%) as good responders [16], were enrolled as
controls. In the validation cohort, 35 Han Chinese poor
responders and 35 Han Chinese good responders were
enrolled. All patients had OS in the long tubular
bones and were treated preoperatively with neoadjuvant
chemotherapy as follows: intravenous (i.v.) doxorubicin
(3 courses at 25–30 mg/m2/day for 3 days), i.v. methotrex-
ate (4 courses of up to 14 g/m2/day for 1 day) and intra-
arterial cisplatin (3 courses at 35 mg/m2/day for 3 days).
All OS diagnoses were based on biopsy and the response
to treatment was determined histologically as the percent-
age of necrosis after neoadjuvant chemotherapy. Patients
with any other malignancies or a family history of OS or
any other cancers were excluded. Baseline characteristics
of all 82 patients are summarized in Table 1. This study
was approved by the Ethics Committee of the Third
Xiangya Hospital, Central South University. Written in-
formed consent was obtained from the parent or guardian
of minor participants before the start of the study.
Cells lines, reagents and plasmid constructs
Saos-2 and MG-63 human OS cell lines were purchased
from the American Type Culture Collection (Manassas,
VA, USA). Human Twist cDNA was subcloned into the
pcDNA 3.1 expression vector [17]. Twist (sc-38604-V)
short hairpin RNA (shRNA) lentiviral particles, control
shRNA lentiviral particles-A (sc-108080), and anti-
TWIST (sc-81417) antibody were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The Dead-
End™ Fluorometric TUNEL System was purchased from
Promega (Madison, WI, USA). Superfect™ transfection
reagent was purchased from Qiagen (Valencia, CA,
USA). Dual-luciferase reporter assay system was
Table 1 Characteristics of study cohorts
Group Discovery cohort Validation cohort
Chemoresistant OS (n=6) Control (n=6) Chemoresistant OS (n=35) Control (n=35)
Age (years)
Mean±SD 9.6±4.2 9.6±4.2 9.9±4.9 10.1±5.2
Range 7–14 7–14 6–16 6–16
Gender n (%)
Male 3 (50) 3 (50) 21 (60) 23 (66)
Female 3 (50) 3 (50) 14 (40) 12 (34)
Tumor stage n (%)
Stage IIA 2 (33) 2 (33) 8 (23) 7 (20)
Stage IIB 2 (33) 2 (33) 13 (37) 13 (37)
Stage III 2 (33) 2 (33) 14 (40) 15 (43)
Body mass index (kg/m2) 17.5±4.0 18.2±4.1 17.7±3.8 18.3±4.0
Tumor necrosis (%) 94.1±2.8 70.8±9.2* 93.5±3.6 73.6±12.2*
Note: OS osteosarcoma. *p < 0.05 vs Chemoresistant OS.
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mycin, cisplatin, and all chemicals of reagent grade were
purchased from Sigma (St. Louis, MO, USA). The 3′-
UTR of TWIST was amplified from genomic DNA using
the following primers: 5′-GCGCCTCGAGCAGGCG-
GAGCCCCCCACCCCCTCA-3′ (forward) and 5′-GCG
CGCGGCCGCGCAGAAAAATATACAAAGATATT-3′
(reverse). The TWIST-3′UTR-luciferase reporter was
generated by inserting the TWIST 3′-UTR between
XhoI and NotI restriction sites (underlined in the
above primers) of the psiCheck2 vector (Promega)
downstream of the renilla luciferase gene. PsiCheck2
vector (Promega) was used as a control vector. TWIST-
mut33-luciferase reporter was generated by site-directed
mutagenesis with the following primers: 5′-TTTATT-
GAGGACCCATGGTAACATATGAATAGATCCGGTG
TCTAAATGC-3′ (forward) and 5′-GCATTTAGACAC
CGGATCTATTCATATGTTACCATGGGTCCTCAATA
AA-3′ (reverse). The miRNA-33 anti-seed sequence was
converted to NdeI restriction site (underlined in the
primers). Antagomir-33a (427064-00hsa-miR-33amiR-
CURY LNA™ microRNA Power inhibitor) was purchased
from Exiqon (Woburn, MA, USA). miRNAs potentially
able to suppress TWIST expression were selected by
using TargetScan prediction software (http://www.tar-
getscan.org). The miR-Vecs (miRNA expressing vectors)
and MSCV-hTR (control vector) constructs were made
as previously described [18].
miRNA microarray analysis
Total RNA from OS tissues of the discovery cohort of pa-
tients was isolated using TRIzol reagent. The integrity of
RNA was confirmed by agarose gel electrophoresis and
its concentration determined by spectrophotometry. Taq-
Man Low Density miRNA Arrays (Applied Biosystems,Carlsbad, CA, USA) was used to assay the expression of
human miRNAs by the manufacturer’s protocol. Manual
inspection of all amplification plots was performed and
miRNAs were excluded from the analysis if CT values
were too high (>35, indicating that a miRNA expression is
too low for accurate detection). Data analysis was per-
formed using SDS 2.3 software (Applied Biosystems),
which utilizes the delta-delta CT method [19].
Real-time quantitative reverse transcription PCR
Total RNA was prepared from OS tissues or cell lines
using TRIzol reagent followed by purification with TURBO
DNA-free System (Ambion, Austin, TX). The cDNAs were
synthesized using SuperScript II reverse transcriptase
(Invitrogen, Carlsbad, CA, USA). Real-time quantitative
PCR was performed using SYBR Green PCR master
mix (Applied Biosystems) in a 7300 Real-time PCR
System (Applied Biosystems). TaqMan microRNA assays
(Applied Biosystems) that include RT primers and
TaqMan probes were used to quantify the expression
of mature miRNA-33a. The mean Ct was determined
from triplicate PCRs. Gene expression was calculated
relative to GAPDH. For measurement of TWIST
mRNA, the following primers were used: for human TWIST,
5′-ACGAGCTGGACTCCAAGATG-3′ (forward) and 5′-
CACGCCCTGTTTCTTTGAAT-3′ (reverse); for human
GAPDH, 5′-GACTCATGACCACAGTCCATGC-3′ (forward)
and 5′-AGAGGCAGGGATGATGTTCTG-3′ (reverse).
The results were normalized against that of the GAPDH
gene in the same sample. Each experiment was repeated
for two times in triplicates.
Western blot analysis
Briefly, cells were dissolved in 250 μl of 2× SDS loading
buffer (62.5 mM TrisHCl, pH 6.8, 2% SDS, 25% glycerol,
Table 3 Down-regulated miRNAs in chemoresistant vs
control osteosarcomas
miRNA Ct (chemoresistant) Ct (control) ΔΔct
hsa-miR-451 33.46 29.79 3.21
hsa-miR-92a 33.29 29.14 4.25
hsa-miR-200a 32.85 28.31 4.54
hsa-miR-15b 32.08 27.15 4.93
hsa-miR-143 31.15 24.85 5.27
hsa-miR-145 30.37 23.66 5.45
hsa-miR-422a 30.15 22.74 6.32
hsa-miR-611 29.72 22.96 6.76
hsa-miR-34c 28.64 21.29 7.35
Table 2 Up-regulated miRNAs in chemoresistant vs
control osteosarcomas
miRNA Ct (chemoresistant) Ct (control) ΔΔct
hsa-miR-132 22.81 29.40 −8.67
hsa-miR-21 25.16 32.13 −7.54
hsa-miR-33a 21.57 28.70 −7.40
hsa-miR-215 26.97 33.13 −6.93
hsa-miR-221 26.15 32.07 −6.90
hsa-miR-140 27.62 32.78 −5.94
hsa-miR-375 22.46 26.92 −4.66
hsa-miR-181a 23.22 28.09 −3.96
hsa-miR-30a 22.62 25.75 −3.53
hsa-miR-25 31.54 33.87 −2.97
hsa-miR-200c 31.96 32.86 −2.61
hsa-miR-26b 26.70 29.17 −2.50
hsa-miR-23a 30.05 33.08 −2.42
hsa-miR-625 29.36 31.12 −2.11
hsa-miR-363 25.73 28.24 −2.09
hsa-miR-17-5p 31.02 32.25 −2.05
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cubated at 95°C for 10 min. Equal amount of proteins for
each sample were separated by 10% SDS-polyacrylamide
gel and blotted onto a polyvinylidene difluoride micropor-
ous membrane (Millipore, Billerica, MA, USA). Mem-
branes were incubated for 1 h with a 1/1000 dilution
of primary antibody, and then washed and revealed
using secondary antibodies with horseradish peroxidase
conjugate (1/5000, 1 h). Peroxidase was revealed with a
GE Healthcare ECL kit (Shanghai, China).
Transfection and lentiviral transduction
Plasmid constructs were transfected into cells using
Superfect™ transfection reagent (Qiagen) according to
the manufacture’s instructions. Pools of stable transfec-
tants of TWIST were generated via selection with G418
(800 μg/ml) by the manufacturer’s protocol. Lentiviral
transduction of TWIST-shRNA was performed and
pools of stable transductants were generated via selec-
tion with puromycin (5 μg/ml).
Luciferase assay
MG-63 cells were transfected with luciferase reporter con-
structs using Superfect™ transfection reagent (Qiagen). Lu-
ciferase activity was measured 72 hours after transfection
using the Dual-luciferase reporter assay system (Promega)
following the manufacturer’s instructions. Experiments
were conducted in triplicates and results were expressed
as ratios between renilla and firefly luciferase counts.
Measurement of apoptosis by TUNEL (terminal
deoxynucleotidyl transferase mediated nick-end labeling)
assay
The TUNEL assay was performed using the DeadEnd™
Fluorometric TUNEL System by the manufacturer’s
protocol (Promega). Cells were treated with cisplatin
(15 nM) for 8 hours. Apoptotic cells exhibit a strong nu-
clear green fluorescence that could be detected using a
standard fluorescein filter. All cells stained with DAPI
exhibit a strong blue nuclear fluorescence. The slides
were observed under fluorescence microscopy with
relative apoptotic cells determined by counting TUNEL-
positive cells in five random fields (magnification, ×100)
for each sample.
Statistical analysis
Statistical analyses were performed with SPSS for
Windows 10.0. All continuous variable values were
expressed as Mean±SD. Comparison of means be-
tween two groups was performed with student t tests.
Comparisons of means among multiple groups were
performed with one-way ANOVA followed by post
hoc pairwise comparisons using Tukey’s tests. A two-tailed p < 0.05 was considered statistically significant
in this study.
Results
miRNA expression profiling in chemoresistant and control
OS
In the discovery cohort, patients were matched by age,
sex and tumor stage. Thus, there was no significant
difference in age, sex and distribution of tumor stages
between poor responders (chemoresistant OS patients,
n = 6, tumor necrosis 70.8% ± 9.2%) and good responders
(control OS patients, n = 6, tumor necrosis 94.1% ± 2.8%)
to neoadjuvant chemotherapy (Table 1). All patients had
OS in the long tubular bones. As the inclusion rate for
adult OS patients was low, we only performed this study
with pediatric OS patients. miRNA microarray analyses
Figure 2 Effects of selected miRNAs on TWIST 3′-untranslated region (UTR). Twelve miRNAs potentially able to regulate TWIST 3′-UTR were
selected based on TargetScan prediction software and individually co-transfected with a TWIST-3′UTR-luciferase reporter in MG-63 cells. Among
the selected miRNAs, miR-33a, miR-25 and miR-363 were differentially expressed between chemoresistant and control osteosarcoma tissues based
on results of the microarray analysis. miRNAs that significantly reduced renilla luciferase activity compared to the control miR-Vec (hTR) (desig-
nated as 1, cut off value: 0.8) were selected for validation (light bars). *p < 0.05 vs 0.8 (cut off value).
Figure 1 Western blot analysis of TWIST expression in chemoresistant and control osteosarcoma (OS) tissues. (A) OS tissue lysates from
the chemoresistant OS and the non-chemoresistant control groups (n = 6 each) were subject to western blot analysis for TWIST expression.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) blotting was used as a loading control. Lanes 1, 3, 5, 7, 9, 11 were samples from the
chemoresistant OS group. Lanes 2, 4, 6, 8, 10, 12 were samples from the control group. (B) Density of the TWIST blots was normalized against
that of GAPDH to obtain a relative blot density. The relative TWIST blot density of the non-chemoresistant control group was expressed as fold
changes to that of the chemoresistant OS group (designated as 1). *p < 0.05 vs chemoresistant OS.
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OS tissues from the chemoresistant OS patients com-
pared with those from the control OS patients, 16 being
up-regulated (Table 2) and 9 down-regulated (Table 3).
Screening of miRNAs able to regulate TWIST
The expression of TWIST in the chemoresistant OS pa-
tients was significantly lower than that in the control OS
patients, either individually or by group (Figure 1), sug-
gesting that TWIST is an important negative regulator
in the development of OS chemoresistance. We screenedFigure 3 Regulation of TWIST 3′-untranslated region (UTR) by miR-33
reporter and miR-33a or control miR-Vec (hTR). The relative luciferase activi
presentation of generation of a TWIST-mut33-luciferase reporter (mut33) by
miR-33a in TWIST 3′-UTR. (C) MG-63 cells were co-transfected with the TWI
miR-33a or control miR-Vec (hTR). The relative luciferase activity in cells co-
hTR was designated as 1. *p < 0.05 vs hTR.for miRNAs able to regulate TWIST in OS. To this pur-
pose, the 3′-UTR of the TWIST gene was inserted
downstream of the renilla luciferase gene in the psi-
Check2 vector to generate a TWIST-3′UTR-luciferase
reporter. By combining the microarray expression data
with results of the prediction software TargetScan, three
up-regulated miRNAs (miR-33a, miR-25 and miR-363)
potentially able to regulate TWIST 3′-UTR were se-
lected and individually tested for their ability to affect
luciferase expression in MG-63 human OS cells co-
transfected with the TWIST-3′UTR-luciferase reporter.a. (A) MG-63 cells were co-transfected with a TWIST-3′UTR-luciferase
ty in cells co-transfected with hTR was designated as 1. (B) Schematic
site-directed mutagenesis of the predicted binding sequence of
ST-3′UTR-luciferase reporter or TWIST-mut33-luciferase reporter and
transfected with the TWIST-3′UTR-luciferase reporter (wild type) and
Figure 4 miR-33a and TWIST levels in osteosarcoma (OS)
tissues from chemoresistant and control OS patients in the
validation cohort. Real-time RT-PCR and Western blot analysis were
performed to determine (A) miR-33a and (B) TWIST protein levels in
OS tissues from the chemoresistant OS and control groups in the
validation cohort (n = 35 each group), respectively. Data are shown
in scatter plots. The mean miR-33a and TWIST protein levels are
marked by a horizontal bar in each group.
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miR-92a, miR-92b, miR-92c, miR-367, miR-137, miR-
137a, and miR-137b) predicted by TargetScan but not
differentially expressed in our microarray analysis were
also assayed (Figure 2). miR-Vec control (hTR) was used
as a negative control. We used MG-63 cells because, ac-
cording to our microarray data, the predicted miRNAs
were absent or expressed at very low levels in the cell line
(data not shown). miR-33a, miR-33b and miR-367 signifi-
cantly reduced renilla luciferase activity compared to the
control miR-Vec (cut off value: 0.8) (Figure 2), and miR-
33a was found the best candidate to significantly and con-
sistently reduce renilla luciferase activity compared to the
control (Figure 3A).
To demonstrate a direct interaction between miR-33a
and TWIST, the potential binding sequence for the
miRNA within the 3′-UTR of TWIST, as predicted by
TargetScan, was mutated to generate a TWIST-mut33-
luciferase reporter (Figure 3B). MG-63 cells were co-
transfected with miR-33a or miR-Vec control together
with either TWIST-3′UTR-luciferase reporter or TWIST-
mut33-luciferase reporter. The reduction of renilla lucifer-
ase activity caused by miRNA-33a was specifically abol-
ished by the mutation of the corresponding anti-seed
sequence (Figure 3C), suggesting that miR-33a could
suppress TWIST expression by acting on its predicted
sequence in the 3′-UTR.
To confirm the findings, we determined miRNA-33a
and TWIST protein levels in chemoresistant OS patients
(n = 35) and control patients (n = 35) in the validation
cohort. As shown in Figure 4A, the chemoresistant OS
group presented a significantly higher range of miR-33a
levels than the control group (0.32 ± 0.08 vs 0.13 ± 0.05;
p < 0.001). On the other hand, the chemoresistant OS group
presented a significantly lower range of TWIST protein
levels than the control group (0.20 ± 0.08 vs 0.67 ± 0.19;
p < 0.001) (Figure 4B). Correlation analyses in the entire val-
idation cohort (n = 70) showed that the miR-33a level was
negatively correlated with the TWIST protein level in the
OS tissue (r = −0.627, p < 0.001). The miR-33a was nega-
tively correlated with the tumor necrosis rate (r =−0.352,
p < 0.001), while the TWIST protein level was positively cor-
related with the tumor necrosis rate (r = 0.562, p < 0.001).
Effect of overexpression and inhibition of miR-33a on
TWIST expression in OS cells
We next examined the effects of miRNA-33a on TWIST
expression in human OS cells. As shown in Figure 5, miR-
33a was highly expressed in Saos-2 cells, which had a low
constitutive expression of TWIST at both the mRNA and
the protein levels. In contrast, MG-63 cells had a constitu-
tive low expression of miR-33a, and a high expression of
TWISTat both the mRNA and the protein levels (Figure 5).
Thus, overexpression and knockdown of TWIST wererespectively performed in the two cell lines to approach
the study objectives. As shown in Figure 6A, inhibition of
miR-33a by antagomir-33a increased TWIST expression
by over 1.5 fold in Saos-2 cells. On the other hand, overex-
pression of miR-33a decreased TWIST expression by
about 30%. Overexpression of TWIST led to an approxi-
mately two-fold increase of TWIST expression in Saos-2
cells, which was largely reversed by overexpression of miR-
33a and doubled by antagomir-33a. As shown in Figure 6B,
overexpression of miR-33a decreased TWIST expression
by nearly 70% in MG-63 cells, while antagomir-33a in-
creased TWIST expression by 0.4 fold. Knockdown of
Figure 5 miR-33a and TWIST levels in osteosarcoma (OS) cells.
Real-time RT-PCR and Western blot analysis were performed to
determine (A) miR-33a and (B) TWIST mRNA and (C) TWIST protein
levels in Saos-2 and MG-63 human OS cells. The miR-33a expression
level and the relative TWIST mRNA level and protein blot density in
MG-63 cells were designated as 1, respectively. *p < 0.05 vs MG-63.
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crease of endogenous TWIST expression in MG-63 cells,
which was partially reversed by antagomir-33a.
Functional role of miR-33a in TWIST-inhibited OS cell
survival against cisplatin
TWIST reportedly decreases OS cell survival against
cisplatin, an apoptosis-inducing chemotherapeutic agent
commonly used to treat OS [10,11,16]. To explore the
effect of interaction between miR-33a and TWIST on
OS chemoresistance, we examined cell apoptosis rate in
both cell lines treated with cisplatin (15 nM) using
TUNEL (terminal deoxynucleotidyl transferase mediated
nick-end labeling) assays. Overexpression or knock-
down/inhibition of TWIST and/or miR-33a did not sig-
nificantly alter cell apoptosis in both Saos-2 and MG-63
cells under normal culture conditions (Figure 7A). In
Saos-2 cells treated with cisplatin, inhibition of miR-33a
by antagomir-33a markedly increased cell apoptosis,
which was enhanced by overexpression of TWIST
(Figure 7B). The apoptosis-inducing effect of TWIST
overexpression was reversed by overexpression of
miR-33a (Figure 7B). In MG-63 cells, overexpression of
miR-33a significantly decreased cisplatin-induced cell
apoptosis, which was enhanced by knockdown of
TWIST (Figure 7C). Antagomir-33a significantly in-
creased cisplatin-induced cell apoptosis, which was re-
versed by knockdown of TWIST (Figure 7C).
Discussion
Chemoresistance is the major reason for poor survival of
OS patients. Previous studies reported that TWIST could
decrease OS cell survival against cisplatin by inhibiting
multiple signaling pathways [10,11], suggesting that
TWIST is a pivotal negative regulator of OS chemoresis-
tance. miRNAs reportedly are involved in the pathogenesis
and chemoresistance of various cancers, including OS. In
the present study, we profiled miRNAs differentially
expressed in chemoresistant OS by microarray analysis,
with a focus to identify miRNAs that regulate TWIST ex-
pression and OS chemoresistance. We provide the first
evidence suggesting that miR-33a promotes OS chemore-
sistance by down-regulating TWIST.
OS is the most common pediatric bone malignancy in
the world [1]. As the inclusion rate for adult OS patients
was low, we performed this study only in pediatric OS pa-
tients. Patients (n = 12) in the discovery cohort were
Figure 6 (See legend on next page.)
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Figure 6 TWIST expression in osteosarcoma cells with overexpression or knockdown/inhibition of TWIST and/or miR-33a. (A) In Saos-2
cells, TWIST expression was determined in normal control cells (NC, lane 1), cells stably transfected with empty pcDNA3 vector (VC, lane 2), cells
overexpressing TWIST (lane 3), cells overexpressing miR-33a (lane 4), cells transfected with antagomir-33a (lane 5), cells overexpressing TWIST
and miR-33a (lane 6), and cells overexpressing TWIST plus transfection of antagomir-33a (lane 7). (B) In MG-63 cells, TWIST expression was
determined in normal control cells (NC, lane 1), cells stably transduced with scramble control shRNA (SC, lane 2), cells stably expressing
TWIST-shRNA (T-shRNA, lane 3), cells overexpressing miR-33a (lane 4), cells transfected with antagomir-33a (lane 5), cells stably expressing
T-shRNA and overexpressing miR-33a (lane 6), and cells stably expressing T-shRNA plus transfection of antagomir-33a (lane 7). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) blotting was used as a loading control. Density of the TWIST blot was normalized against that of GAPDH
to obtain a relative blot density, which was expressed as fold changes to the relative TWIST blot density of NC cells (designated as 1). In (A)
Saos-2 cells, ap < 0.05 vs NC and VC; bp < 0.05 vs TWIST; cp < 0.05 vs miR-33a; dp < 0.05 vs antagomir-33a. In (B) MG-63 cells, ap < 0.05 vs NC and
SC; bp < 0.05 vs T-shRNA; cp < 0.05 vs miR-33a; dp < 0.05 vs antagomir-33a; ep < 0.05 vs T-shRNA +miR-33a.
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of confounders on miRNA profiling between chemoresis-
tant and control OS samples. Patients (n = 70) in the valid-
ation cohort were not matched in order to verify the
profiling findings in a more generalizable setting. Among
the up-regulated miRNAs identified in chemoresistant OS
samples in this study, miR-140, miR-215 and miR-221 have
been reported to induce human OS chemoresistance
[20-22]. Among the down-regulated miRNAs identified in
chemoresistant OS samples, miR-451 and miR-15b have
been reported to increase chemosensitivity of OS [13].
Thus, our findings were in agreement with previous stud-
ies, indicating good reliability of the data.
High expression of TWIST has been detected in sev-
eral cancers and has been associated with the initial
phase of metastatic progression [23]. One recent study
reported that TWIST overexpression correlated with
disease progression and a poor clinical outcome in OS
patients [23]. On the other hand, it has been reported
that in homogeneous cohort of OS patients, the TWIST
gene was frequently deleted in the tumors at diagnosis,
and its haploinsufficiency was significantly correlated
with a poorer patient outcome [6,9]. In addition, two re-
cent studies reported that TWIST could decrease OS cell
survival against cisplatin by inhibiting β-catenin signaling
and endothelin-1/endothelin A receptor signaling path-
ways [10,11], suggesting that TWIST is an important
negative regulator in the development of OS chemoresis-
tance. In this study, our in vitro results showed that
overexpression and knockdown of TWIST increased and
decreased cisplatin-induced OS cell apoptosis, respect-
ively. This was corroborated by our findings that the ex-
pression of TWIST in the chemoresistant OS group was
significantly lower than that in the control OS group in
both the discovery and validation cohorts, which provides
further evidence supporting a critical counteracting role of
TWIST in the development of OS chemoresistance.
With an aim to identify miRNAs regulating TWIST ex-
pression in OS, we found that miR-33a could significantly
down-regulate TWIST expression, which was supported
by an inverse miRNA-33a/TWIST expression trend in the
validation cohort, target-sequence-specific inhibition ofTWIST-3′UTR-luciferase reporter activity by miR-33a,
and alteration of TWIST expression by overexpression or
inhibition of miR-33a in human OS cell lines. Saos-2 and
MG-63 cells were employed as OS cell models in this
study. Saos-2 cells have a constitutive high expression of
miR-33a and low expression of TWIST, while MG-63 cells
have a constitutive low expression of miR-33a and high
expression of TWIST. This explains why inhibition of
miR-33a by antagomir-33a had more pronounced effects
on TWIST expression than overexpressing miR-33a in
Saos-2 cells. Likewise, overexpressing miR-33a had
more pronounced effects on TWIST expression than
antagomir-33a treatment in MG-63 cells. The effects of
overexpression and inhibition of miR-33a on TWIST ex-
pression significantly altered OS cell resistance to cis-
platin, a chemotherapeutic agent routinely used in
neoadjuvant chemotherapy for OS [16]. In the presence of
cisplatin, antagomir-33a significantly enhanced cisplatin-
induced apoptosis in both Saos-2 and MG-63 cells, sug-
gesting that inhibition of miR-33a could be a potential
new strategy to enhance neoadjuvant chemotherapy for
OS. The effects of antagomir-33a was reversed and en-
hanced by knockdown and overexpression of TWIST, re-
spectively, indicating that miR-33a promotes OS cell
resistance to cisplatin by down-regulating TWIST, or
antagomir-33a enhances cisplatin-induced OS cell apop-
tosis by up-regulating TWIST. miR-33a has been shown
to regulate genes involved in fatty acid metabolism and in-
sulin signaling [24]. A recent study indicated that miR-33a
targets the proto-oncogene Pim-1 and suggested overex-
pression of miR-33a as an anticancer treatment [25]. How-
ever, another study described the down-regulation of
tumor suppressor p53 by miR-33 [26], suggesting a com-
plex and possible context-dependent response to miR-33
manipulations. As p53 is often mutated in OS [27], it is
unlikely that miR-33a promotes OS chemoresistance
through down-regulating p53-induced apoptosis. Thus,
the enhancing effect of miR-33a on OS chemoresistance
via down-regulating TWIST expression is a new function
of this miR, and the miR-33a/TWIST signaling could
be a novel mechanism involved in development of OS
chemoresistance.
Figure 7 Cisplatin-induced apoptosis in osteosarcoma cells
with overexpression or knockdown/inhibition of TWIST and/or
miR-33a. In Saos-2 cells, TUNEL (terminal deoxynucleotidyl transfer-
ase mediated nick-end labeling) assays were performed in normal
control cells (NC), cells stably transfected with empty pcDNA3 vector
(VC), cells overexpressing TWIST, cells overexpressing miR-33a, cells
transfected with antagomir-33a, cells overexpressing TWIST and
miR-33a, and cells overexpressing TWIST plus transfection of
antagomir-33a. In MG-63 cells, TUNEL assays were performed in
normal control cells (NC), cells stably transduced with scramble
control shRNA (SC), cells stably expressing TWIST-shRNA (T-shRNA),
cells overexpressing miR-33a, cells transfected with antagomir-33a,
cells stably expressing T-shRNA and overexpressing miR-33a, and
cells stably expressing T-shRNA plus transfection of antagomir-33a.
(A) The cells were under normal culture conditions for 8 hours. The
cell apoptosis rate at 8 hours was expressed as fold changes to that
of the Saos-2 NC cells (designated as 1). (B) Saos-2 and (C) MG-63
cells were treated with 15 nM of cisplatin for 8 hours. The cell
apoptosis rates at 4 hours and 8 hours were shown as the
percentage of TUNEL positive cells in total cells.
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was only performed in pediatric OS patients. Despite that
adult OS patients only occupy a small portion of total OS
patients, it would still be interesting to verify the findings
in adult patients in future studies. [2] Cisplatin elicits
DNA repair mechanisms by crosslinking DNA, which in
turn activates apoptosis when repair proves impossible
[28]. In this study, we only examined the effect of miR-
33a/TWIST signaling on OS cell resistance to cisplatin. It
is unclear whether miR-33a/TWIST would impact OS cell
resistance to other types of chemotherapy agents. Further
studies with more types of chemotherapy agents and OS
cell lines would elaborate this issue.
In conclusion, we demonstrate that miR-33a is up-
regulated in chemoresistant OS and that the miR-33a
level is negatively correlated with the TWIST protein
level and the tumor necrosis rate in OS. Our in vitro
data indicate that miR-33a promotes OS cell resist-
ance to cisplatin by down-regulating TWIST; on the
other hand, inhibition of miR-33a by antagomir-33a
enhances cisplatin-induced apoptosis in OS cells by
up-regulating TWIST expression. The findings suggest
that inhibition of miR-33a/TWIST signaling could
be a potential new strategy to enhance neoadjuvant
chemotherapy for OS.
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